U-Blot® FGFR3 hIgG1 Reference Antibody(Vofabio)

Background:Vofatamab is an anti-FGFR3 monoclonal antibody that acts as an FGFR3 antagonist to block activation of wild-type and gene-activated receptors, it is used to treat metastatic urothelial cancer (MUC, a type of bladder cancer) that carries FGFR3 mutations or fusion genes, which are present in 15% to 20% of patients with advanced disease. The drug inhibits tumor growth by specifically targeting the FGFR3 signaling pathway and has shown significant efficacy in clinical trials in combination with docetaxel or PD-1 inhibitors.